RSV Vaccine Approved, Now Waiting on Pharmac | Auckland News

Medsafe just approved Beyfortus, a groundbreaking RSV vaccine for newborns and young kids that could slash hospitalizations by up to 80%—but now the real race is on Pharmac to fund it before next winter. With RSV hitting babies hard and straining hospitals, pediatricians are desperate for prevention. While Beyfortus is already approved in 40+ countries including Australia, Pharmac’s decision could make or break its impact. They’re already funding one RSV preventative and reviewing two others—including one for pregnant moms—to protect babies from birth. The clock is ticking: April is the deadline to get kids protected for the coming season. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/42bc7d987bd5e9ee